• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Novo Nordisk A/S

    5/22/25 6:41:41 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVO alert in real time by email
    SD 1 dp229141_sd.htm FORM SD

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     Washington, D.C. 20549

     

    FORM SD

     

    Specialized Disclosure Report

     

    NOVO NORDISK A/S 
    (Exact name of the registrant as specified in its charter)

     

    The Kingdom of Denmark 333-82318 N/A

    (State or other jurisdiction of

    Incorporation or organization)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

     

    Novo Allé, DK-2880 Bagsværd, Denmark   N/A
    (Address of principal executive offices)   (Zip code)

     

    Karsten Munk Knudsen +45 4444 8888

    (Name and telephone number, including area code, of the

    person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
     
    ☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    Section 1 - Conflict Minerals Disclosure

     

    Items 1.01 and 1.02 Conflict Minerals Disclosure and Report, Exhibit

     

    Conflict Minerals Disclosure

     

    A copy of Novo Nordisk A/S’s Conflict Minerals Report for the year ended December 31, 2024 is provided as Exhibit 1.01 hereto and is publicly available at: https://www.novonordisk.com/sustainable-business/esg-portal/transparency-disclosures-.html.

     

    Section 2 – Exhibits

     

    Item 2.01 Exhibits

     

    Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Date: May 20, 2025 NOVO NORDISK A/S
       
       
      By: /s/ Karsten Munk Knudsen
      Name: Karsten Munk Knudsen
      Title: Executive Vice President & Chief Financial Officer

     

    Get the next $NVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVO

    DatePrice TargetRatingAnalyst
    4/17/2025$64.00Outperform → Market Perform
    BMO Capital Markets
    3/13/2025Hold → Buy
    Kepler
    3/3/2025Buy → Hold
    Stifel
    2/12/2025Equal-Weight
    Morgan Stanley
    1/6/2025Underperform → Mkt Perform
    Bernstein
    5/30/2024$156.00Buy
    Goldman
    4/12/2024$163.00Outperform
    BMO Capital Markets
    1/23/2024$120.00Overweight
    Morgan Stanley
    More analyst ratings

    $NVO
    SEC Filings

    See more
    • SEC Form SD filed by Novo Nordisk A/S

      SD - NOVO NORDISK A S (0000353278) (Filer)

      5/22/25 6:41:41 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/16/25 8:28:11 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/9/25 8:12:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

      With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptionsNew, one-time $199 first-month offer for Wegovy® available through June 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide"Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredientsPLAINSBORO, N.J., May 22, 2025 /P

      5/22/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

      The Wegovy® savings offer is good for all dose strengths of Wegovy® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choicePLAINSBORO, N.J., March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month. Until today, the $499-per-month offer for Wegovy® was only available via the recently launched NovoCare® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them acces

      3/24/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients

      NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverageAmidst the dangers of fake or illegitimate compounded "semaglutide," NovoCare® Pharmacy offers reliable access to authentic, FDA-approved Wegovy® in our once-weekly, single-dose pen PLAINSBORO, N.J., March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts to ensure patients who need Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access i

      3/5/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

      3/8/24 2:00:18 PM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • EXL Announces Appointment of Andreas Fibig to Board of Directors

      NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo

      1/12/23 4:01:00 PM ET
      $EXLS
      $IFF
      $NVO
      Business Services
      Consumer Discretionary
      Major Chemicals
      Industrials
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Novo Nordisk A/S downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00

      4/17/25 8:30:12 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S upgraded by Kepler

      Kepler upgraded Novo Nordisk A/S from Hold to Buy

      3/13/25 8:17:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S downgraded by Stifel

      Stifel downgraded Novo Nordisk A/S from Buy to Hold

      3/3/25 7:34:14 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care